{
}
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for non-alcoholic steatohepatitis (NASH). Its lead candidate, resmetirome, is a once-daily oral thyroid hormone receptor agonist aimed at addressing the primary causes of NASH. The company's clinical programs include MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Novo Nordisk plans to seek regulatory approval for semaglutide as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) after positive Phase 3 trial results. The study showed significant improvements in liver scarring and resolution of MASH among patients receiving semaglutide compared to placebo. Despite the promising findings, analysts remain cautious about its competitive edge in the MASH treatment landscape.
Madrigal Pharmaceuticals has seen its price target increased to $441 from $411 by UBS. This adjustment reflects a positive outlook for the company, as reported by TipRanks.com, a leading source for real-time financial news.
Madrigal Pharmaceuticals, Inc.
Companies
| Symbol | MDGL |
| Name | Madrigal Pharmaceuticals, Inc. |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | United States |
| State | PA |
| City | West Conshohocken |
| Zipcode | 19428 |
| Website | http://www.madrigalpharma.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Madrigal Pharmaceuticals advances treatment for non-alcoholic steatohepatitis with resmetirome
16:11 01.11.2024
novo seeks approval for semaglutide as treatment for liver disease
United States Dollar
Eli Lilly and Company
Akero Therapeutics, Inc.
Novo Nordisk A/S
Zealand Pharma A/S
Intercept Pharmaceuticals Inc.
Madrigal Pharmaceuticals, Inc.
Boehringer Ingelheim KG
89bio, Inc.
DNK
Thomas Smith
Andy Hsieh
Brian Abrahams
Martin Holst Lange
William Blair
Show more
15:45 01.11.2024
Madrigal Pharmaceuticals price target increased to 441 by UBS
13:23 01.11.2024
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Global Trade Developments
Global Financial Events
Finance Mergers & Acquisitions
Banking Regulations
Retail and Consumer Goods
Startups & Entrepreneurship
Industry Mergers & Acquisitions
Market Analysis and Predictions
CEO Changes
Inflation and Monetary Impact
Government Policies
Government Economic Policies
Commodities
GDP Growth & Recession Forecasts
Central Bank Actions
Hedge Funds & Private Equity
Domestic Politics
Countries:
Companies:
Barclays PLC
JPMorgan Chase & Co.
Apple Inc.
Tesla, Inc.
Banco Santander, S.A.
Berkshire Hathaway Inc.
The Goldman Sachs Group, Inc.
Commerzbank AG
NVIDIA Corporation
Morgan Stanley
Amazon.com, Inc.
Lloyds Banking Group plc
Bank of America Corporation
Wells Fargo & Company
SpaceXCoin USD
Deutsche Bank Money Market PP
Citigroup Inc.
Royal Bank of Canada
Microsoft Corporation
UBS Group AG
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Indian Rupee
Japanese Yen
Chinese Yuan
New Taiwan Dollar
Canadian Dollar
United Arab Emirates Dirham
South Korean Won
Vietnamese Đồng
Danish Krone
Indonesian Rupiah
Russian Ruble
Singapore Dollar
Chilean Peso
Egyptian Pound
Cambodian Riel
People: